View Older Stories View More Recent Stories

Feb 25, 2019 12:46PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 25, 2019 12:45PM Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 11, 2019 07:07AM Sanofi (SNY) and Regeneron (REGN) to Offer Praluent at 60% Discount
Feb 11, 2019 07:00AM Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 4, 2019 05:57AM UPDATE: Sanofi (SNY), Regeneron (REGN) Report CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Feb 4, 2019 01:01AM Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
Jan 7, 2019 05:59AM Regeneron (REGN), Sanofi (SNY) Report Restructuring of Immuno-Oncology Collaboration for Discovery and Development Programs
Jan 7, 2019 02:31AM Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Dec 3, 2018 01:40PM Sanofi (SNY) Company, Bioverativ, Reports Updated BIVV001 Phase 1/2a Data
Dec 3, 2018 01:32PM BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A
Dec 1, 2018 12:00PM At ASH, Extended Half-Life Therapies ELOCTATE® and ALPROLIX® Demonstrate Proven Efficacy and Well-Characterized Safety over Four Years
Nov 12, 2018 06:17AM Regeneron (REGN), Sanofi (SNY) Report New Analyses from ODYSSEY OUTCOMES Trial for Praluent (alirocumab) Injection
Nov 11, 2018 08:17AM Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
Nov 11, 2018 08:15AM ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause
Nov 7, 2018 05:13PM Regeneron (REGN), Sanofi (SNY) announce NEJM published positive detailed results from Praluent cardiovascular outcomes trial
Nov 7, 2018 05:06PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
Nov 7, 2018 05:00PM New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial
Nov 6, 2018 08:18AM Sanofi (SNY), Regeneron (REGN) Report FDA Priority Review Acceptance of Supplemental Biologics License Application for Dupixent
Nov 6, 2018 08:00AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 6, 2018 01:01AM FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Nov 1, 2018 09:22AM New Data at ASH Showcase Bioverativ’s Commitment to Transforming Care for People with Hemophilia and Other Rare Blood Disorders
Oct 22, 2018 06:06AM Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Asthma Indication for Dupixent (dupilumab)
Oct 19, 2018 05:59PM Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
Oct 19, 2018 05:55PM FDA approves asthsma indication for Dupixent® (dupilumab)
Oct 16, 2018 08:00AM Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Oct 16, 2018 05:45AM Regeneron (REGN) Reports Positive Topline Result in Two Phase 3 Trials Evaluating Dupixent (dupilumab) in Patients with Chronic Rhinosinusitis with Nasal Polyps
Oct 16, 2018 01:01AM Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
Sep 28, 2018 04:46PM Regeneron (REGN), Sanofi (SNY) Report Approcal of Libtayo (cemiplimab), the First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 28, 2018 04:41PM Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 28, 2018 04:40PM FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Sep 17, 2018 07:30AM National Meningitis Association Urges Parents to Get Their Teens The 16 Vaccine to Help Protect Against Meningococcal Meningitis
Sep 17, 2018 05:49AM Regeneron (REGN), Sanofi (SNY) Highlight Positive Phase 3 Results Presented for Dupixent (dupilumab) at 2018 EADV Congress
Sep 15, 2018 02:04AM Sanofi: Positive Phase 3 results presented for Dupixent® (dupilumab)
Sep 12, 2018 08:00AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Sep 12, 2018 01:01AM FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
Aug 7, 2018 08:16AM Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
Jun 11, 2018 07:00AM Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccines for Infectious Diseases using Novel mRNA Technology
Jun 4, 2018 02:18PM Sanofi (SNY), Regeneron (REGN) Announce NEJM Published Pivotal Cemiplimab Trials showing Positive Results in Advanced CSCC
Jun 4, 2018 02:16PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:16PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
Jun 4, 2018 02:15PM New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
May 21, 2018 02:16PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:16PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:15PM Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 21, 2018 02:15PM Regeneron (REGN) Says NEJM Published Two Positive Phase 3 Trials Showing DUPIXENT Improved Moderate-to-Severe Asthma
May 21, 2018 02:15PM New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 16, 2018 05:04PM Regeneron (REGN), Sanofi (SNY) Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
May 16, 2018 08:00AM Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
View More Recent Stories View Older Stories